BiorXiv | Dec 2019

Identifying Novel Targets by using Drug-binding Site Signature: A Case Study of Kinase Inhibitors

Did You Know?

Over 1000 antibodies went through 2bind‘s antibody lead selection and developability pipeline since 2017.

Work with the experts in biophysics!

Im Gewerbepark D19a
93059 Regensburg

+49 941 2000 0890
info@2bind.com